Code | CSB-E09941h |
Size | 96T,5×96T,10×96T |
Price | Request a Quote |
Trial Size |
24T ELISA Kit Trial Size (Only USD$150/ kit) * Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase within six months until depleted. More details >> Interested in a trial size? Please leave a message below.
|
Have Questions? | Leave a Message or Start an on-line Chat |
Intra-assay Precision (Precision within an assay): CV%<8% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three samples of known concentration were tested twenty times on one plate to assess. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inter-assay Precision (Precision between assays): CV%<10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three samples of known concentration were tested in twenty assays to assess. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
To assess the linearity of the assay, samples were spiked with high concentrations of human PARC/CCL18 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. | |||||||||||||
| Sample | Serum(n=4) | |||||||||||
1:100 | Average % | 91 | |||||||||||
Range % | 87-94 | ||||||||||||
1:200 | Average % | 97 | |||||||||||
Range % | 95-103 | ||||||||||||
1:400 | Average % | 98 | |||||||||||
Range % | 95-102 | ||||||||||||
1:800 | Average % | 93 | |||||||||||
Range % | 91-98 | ||||||||||||
The recovery of human PARC/CCL18 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | |||||||||||||
Sample Type | Average % Recovery | Range | |||||||||||
Serum (n=5) | 91 | 87-94 | |||||||||||
EDTA plasma (n=4) | 98 | 95-102 | |||||||||||
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. | |||||||||||||
pg/ml | OD1 | OD2 | Average | Corrected | |||||||||
2000 | 2.466 | 2.585 | 2.526 | 2.394 | |||||||||
1000 | 1.991 | 1.944 | 1.968 | 1.836 | |||||||||
500 | 1.482 | 1.567 | 1.525 | 1.393 | |||||||||
250 | 1.213 | 1.130 | 1.172 | 1.040 | |||||||||
125 | 0.832 | 0.900 | 0.866 | 0.734 | |||||||||
62.5 | 0.477 | 0.450 | 0.464 | 0.332 | |||||||||
31.25 | 0.244 | 0.251 | 0.248 | 0.116 | |||||||||
0 | 0.129 | 0.135 | 0.132 |
|
The ELISA Kit is designed for quantitatively measuring human PARC levels in samples, including serum, plasma, cell culture supernates, or tissue homogenates. It uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of PARC in samples. The color intensity is measured at 450 nm via a microplate reader.
PARC, also known as CCL18, is a chemokine primarily expressed in monocytes, macrophages, and immature dendritic cells and plays a crucial role in immune and inflammation responses. CCL18 attracts lymphocytes and immature dendritic cells and induces collagen deposition by fibroblasts. Recent studies have found that CCL18 is associated with the progression of malignant tumors. It is predominantly derived from breast tumor-associated macrophages (TAMs). Previous data indicate that the CCL18/Nir1 signaling promotes the invasion, metastasis, and EMT of breast cancer cells through the PI3K/Akt/GSK3β/Snail signaling pathway. CCL18 also reduces proliferation in non-small cell lung cancer cells and pre-B acute lymphocytic leukemia cells but enhances proliferation in breast cancer, diffuse large B cell lymphoma, ovarian cancer, osteosarcoma, and urothelial carcinoma.
There are currently no reviews for this product.